biotech · Fibrostenotic Crohn’s disease · liver cirrhosis · AGMB
Agomab Therapeutics NV
Agomab Therapeutics NV is a biotech organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker AGMB. Primary therapeutic focus areas include Fibrostenotic Crohn’s disease, liver cirrhosis, Fibrostenotic
Tel Aviv, USA HQ
2011 Founded
20 Employees
Public company Type
AGMB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 4
AGMB-447
Phase 1 · small molecule · IPF
AGMB-447 for IPF is a Phase 1 program (small_molecule) at Agomab Therapeutics NV with 1 ClinicalTrials.gov record(s).
Internal code AGMB-447-C101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Agomab Therapeutics NV
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- IPF
- Status
- active
- Trials
- 1